A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Trial Profile

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TOPAZ
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 28 Oct 2017 Results of analysis providing updated pregnancy outcomes in alemtuzumab-treated female patients from the clinical development program trials (NCT00050778, [NCT00530348, NCT00548405, NCT00930553, NCT02255656) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results of 5-year follow-up after alemtuzumab (TOPAZ study) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results evaluating 7 year efficacy/safety of alemtuzumab in CARE-MS I patients who received alemtuzumab presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top